It’s been a busy couple of weeks, with a teething baby eating my sleep and job applications eating my time, so a longer written piece is off the cards for now. It seems my piece on new cancer treatments, specifically immunotherapy, however, was a timely one, as it’s hitting the news again, with big successes reported in the use of modified T-cell therapy to treat blood cancers, reported in the Guardian here. These include some startling trial results:
In the most promising study, about 35 patients with ALL were treated with Cars-modified T-cells; 94% went into remission, though symptoms could reappear. More than 40 patients with lymphoma have also been treated, with remission rates of more than 50%. In a group with non-Hodgkin’s lymphoma, there was evidence of diminished cancer symptoms in more than 80% of cases.
These are really impressive figures. Is it just hype? These results were reported at a major scientific meeting, and the ALL (acute lymphoblastic leukaemia) trial results are described as being under review and pending publication. So it’s not just a press release from a laboratory that has been wildly spun out of all proportion by an over-enthusiastic press. I for one will definitely be wanting to read the original research paper when (if) it is published. We can expect to see a flood of trial results and papers published within the next couple of years, if it lives up to even half of its original promise.